“We delivered another quarter of impressive financial performance, as well as substantial deal activity,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “We were thrilled to acquire royalties on three innovative therapies, increasing our announced value of transactions to $3.8 billion this year. Notably, we acquired additional royalties on Evrysdi, a blockbuster rare genetic disease therapy, for up to $1.5 billion, and we also completed two synthetic royalty transactions for up to $650 million. This further underscores the enormous opportunity to fund innovation in life sciences and our unique capabilities to customize win-win solutions for our partners. Our deal pipeline is robust and 2023 is shaping up to be among our best years ever for capital deployment. As a result, we are on track to deliver our attractive long-term financial outlook for compounding growth and value creation.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RPRX:
- Royalty Pharma Reports Third Quarter 2023 Results
- Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
- PTC Therapeutics signs royalty agreement with Royalty Pharma for Evrysdi
- Royalty Pharma Declares Fourth Quarter 2023 Dividend
- Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023